Study guide
12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies
Key Takeaways Explain This Topic AI
Skin and soft tissue infections are dichotomized into non-purulent (cellulitis, erysipelas: predominantly beta-hemolytic streptococci requiring cefazolin or cephalexin) and purulent (abscess, carbuncle: primary management is incision and drainage, reserving MRSA coverage for systemic symptoms or high-risk features).
The CDC 2021 STI Treatment Guidelines updated first-line gonorrhea therapy to high-dose ceftriaxone 500 mg IM monotherapy (<150 kg; 1 g if >=150 kg), eliminating routine oral azithromycin co-treatment.
Chlamydia trachomatis is treated with doxycycline 100 mg PO twice daily for 7 days; azithromycin 1 g single dose is now considered alternative therapy due to inferior microbiologic cure rates in rectal and pharyngeal infections.
Syphilis of primary, secondary, or early latent duration requires benzathine penicillin G 2.4 million units IM single dose; outpatient pelvic inflammatory disease (PID) requires ceftriaxone 500 mg IM plus doxycycline 100 mg PO BID and metronidazole 500 mg PO BID for 14 days.
Doxycycline (100 mg PO/IV BID) represents the unequivocal first-line therapy for Rocky Mountain Spotted Fever (RMSF) and Lyme disease across all age groups, including young children and pregnant patients with life-threatening rickettsial infection.
Last updated: October 2026
12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies
Note
Independent BCEMP study resource provided by ExamFinch. Content is organized around emergency medicine pharmacotherapy principles tested on clinical specialist certification examinations.
Skin & Soft Tissue Infection (SSTI) Classification & Management
Skin and soft tissue infections (SSTIs) are among the most frequent infectious diagnoses encountered in the emergency department. The Infectious Diseases Society of America (IDSA) categorizes SSTIs into two broad clinical presentations: non-purulent and purulent, further stratified by severity (mild, moderate, or severe).
Non-Purulent SSTIs (Cellulitis and Erysipelas)
Pathophysiology & Microbiology : Non-purulent infections involve diffuse dermal and subcutaneous inflammation without macroscopic purulence, fluctuance, or abscess formation. Over 90% of cases are caused by beta-hemolytic streptococci ( Streptococcus pyogenes [Group A Strep], Streptococcus agalactiae [Group B Strep], and Streptococcus dysgalactiae [Groups C and G]). Methicillin-susceptible Staphylococcus aureus (MSSA) is a secondary pathogen.
Clinical Distinction :
Erysipelas : Acute superficial cutaneous involvement with fiery red erythema, raised, sharply demarcated margins, and rapid dermal lymphatic involvement.
Cellulitis : Deeper dermis and subcutaneous fat involvement with warmth, edema, and indistinct, poorly demarcated advancing borders.
Empiric Regimens :
Mild (Outpatient) : Cephalexin 500 mg PO every 6 hours (or Cefadroxil 500 mg PO every 12 hours). In patients with non-severe penicillin allergies: Clindamycin 300-450 mg PO every 8 hours (if local streptococcal resistance is low) or Cefadroxil.
Moderate / Severe (Inpatient) : Cefazolin 1 g to 2 g IV every 8 hours.
Antimicrobial Stewardship Pitfall :
Reflexive prescription of trimethoprim-sulfamethoxazole (TMP-SMX) or doxycycline to cover community-acquired MRSA (CA-MRSA) for typical non-purulent cellulitis is not recommended. Multiple randomized clinical trials demonstrate that adding TMP-SMX to cephalexin provides no improvement in clinical cure rates for uncomplicated cellulitis. TMP-SMX and doxycycline have unreliable, erratic activity against beta-hemolytic streptococci.
Purulent SSTIs (Cutaneous Abscesses, Furuncles, Carbuncles)
Pathophysiology & Microbiology : Purulent SSTIs feature a circumscribed collection of pus in the dermis or deeper tissues, primarily driven by Staphylococcus aureus , with CA-MRSA accounting for 70% to 80% of isolates in many emergency departments.
Definitive Treatment :
Incision and drainage (I&D) is the primary definitive therapeutic intervention . Evacuation of pus, probing loculations, and appropriate wound management achieve cure in the vast majority of simple, localized abscesses without antibiotics.
Indications for Systemic Antibiotics Post-I&D :
Systemic signs of toxicity: fever (>38.0°C), tachycardia (>90 bpm), tachypnea (>20 breaths/min), or leukocytosis (>12,000 cells/mcL)
- Severe immunocompromise, active chemotherapy, or neutropenia
- Extremes of age (neonates/infants or frail elderly)
- Multiple abscess sites or rapidly progressive surrounding cellulitis
- Difficult-to-drain anatomical locations (face, hands, feet, genitalia)
- Lack of response to prior incision and drainage alone
Antimicrobial Regimens for Purulent SSTI :
Oral (Outpatient) : Trimethoprim-sulfamethoxazole (TMP-SMX) 1 to 2 Double Strength (DS) tablets PO twice daily; OR Doxycycline 100 mg PO twice daily for 5 to 7 days.
Intravenous (Hospitalized / Severe) : Vancomycin 15-20 mg/kg IV every 8-12 hours; OR Daptomycin 6-8 mg/kg IV once daily.
Sexually Transmitted Infections: CDC 2021 Guideline Paradigms
The CDC Sexually Transmitted Infections Treatment Guidelines establish critical changes in first-line dosing, duration, and co-treatment paradigms.
CDC STI Treatment Matrix
Infection / Pathogen Clinical Presentation CDC First-Line Recommended Regimen Key Clinical Considerations
Neisseria gonorrhoeae (Gonococcal urethritis, cervicitis, proctitis) Dysuria, profuse purulent discharge, pelvic pain Ceftriaxone 500 mg IM single dose (<150 kg); Ceftriaxone 1 g IM single dose (≥150 kg) Azithromycin co-treatment is eliminated due to resistance. Add Doxycycline 100 mg PO BID x 7d only if Chlamydia has not been ruled out.
Chlamydia trachomatis (Chlamydial urethritis, cervicitis) Mucopurulent cervicitis, watery discharge, often asymptomatic Doxycycline 100 mg PO BID x 7 days Azithromycin 1 g PO is now second-line (inferior rectal/pharyngeal cure). Azithromycin remains first-line in pregnancy.
Treponema pallidum (Primary, Secondary, Early Latent Syphilis) Painless chancre (primary), diffuse rash on palms/soles (secondary) Benzathine Penicillin G 2.4 million units IM as a single dose Administered as two 1.2 million unit injections. Bicillin L-A only! Never use Bicillin C-R or IV formulations.
Treponema pallidum (Late Latent, Latent Unknown Duration) Asymptomatic seropositivity >1 year duration Benzathine Penicillin G 2.4 million units IM weekly for 3 doses Total 7.2 million units at 7-day intervals. In pregnancy, a gap of more than 9 days requires restarting the series; outside pregnancy, limited data suggest 10 to 14 days may be acceptable.
Pelvic Inflammatory Disease (PID) (Outpatient Regimen) Pelvic pain, cervical motion tenderness, adnexal fullness Ceftriaxone 500 mg IM single dose PLUS Doxycycline 100 mg PO BID x 14 days PLUS Metronidazole 500 mg PO BID x 14 days Metronidazole provides critical anaerobic coverage ( Bacteroides fragilis ) and treats bacterial vaginosis.
Trichomonas vaginalis Copious frothy green discharge, strawberry cervix Metronidazole 500 mg PO BID x 7 days (women); Metronidazole 2 g PO single dose (men) Single 2 g dose has higher failure rates in females. Re-screen in 3 months. Avoid alcohol (disulfiram-like reaction).
Gonorrhea: The High-Dose Ceftriaxone Monotherapy Shift
In previous guidelines, dual therapy with ceftriaxone 250 mg IM plus oral azithromycin 1 g was standard. The CDC updated this recommendation to ceftriaxone 500 mg IM monotherapy (<150 kg; 1000 mg IM if ≥150 kg) based on:
Rapid emergence of macrolide resistance among Neisseria gonorrhoeae isolates globally.
Pharmacokinetic/pharmacodynamic data showing that ceftriaxone 500 mg achieves prolonged free concentrations above the MIC in pharyngeal, urogenital, and rectal mucosa, overcoming strains with elevated cephalosporin MICs.
Routine azithromycin co-treatment exerted adverse collateral selection pressure on respiratory and enteric flora.
Syphilis Safety Alerts & The Jarisch-Herxheimer Reaction
Caution
Look-Alike / Sound-Alike Drug Danger : Bicillin L-A (pure benzathine penicillin G) must never be confused with Bicillin C-R (a mixture of benzathine penicillin G and procaine penicillin G). Bicillin C-R produces lower, transient serum concentrations that lead to clinical treatment failure in syphilis. In addition, benzathine penicillin G must NEVER be administered intravenously ; accidental IV administration causes microvascular embolism, cardiopulmonary arrest, and immediate death.
Jarisch-Herxheimer Reaction : An acute systemic febrile reaction occurring within 2 to 24 hours after the first dose of penicillin in patients with spirochetal infections (most common in secondary syphilis, ~50-75% of patients). Driven by the massive release of endotoxin-like pyrogens from dying treponemes, patients develop high fevers, rigors, tachycardia, hypotension, flushing, and exacerbation of their cutaneous lesions.
Emergency Management : This reaction is not an allergic hypersensitivity . Do not discontinue penicillin or label the patient as allergic. Management is entirely supportive with antipyretics (acetaminophen, ibuprofen), IV fluid resuscitation, and patient reassurance.
Note
Doxycycline post-exposure prophylaxis (doxy-PEP) : CDC's 2024 guideline recommends a single doxycycline 200 mg dose within 72 hours after condomless sex for men who have sex with men and transgender women with a bacterial STI in the past 12 months. Doxy-PEP reduces syphilis, chlamydia and gonorrhea. During benzathine penicillin shortages, CDC also lists doxycycline 100 mg twice daily (14 days for early syphilis, 28 days for late or unknown duration) for non-pregnant adults.
Vector-Borne Emergencies: Rocky Mountain Spotted Fever & Lyme Disease
Tick-borne emergencies are seasonal clinical challenges presenting to emergency departments from spring through autumn. Prompt recognition and immediate empiric antimicrobial therapy are life-saving.
Rocky Mountain Spotted Fever (RMSF - Rickettsia rickettsii )
Transmission & Geography : Transmitted by Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick). Endemic across the South Atlantic and south-central states (North Carolina, Tennessee, Oklahoma, Arkansas, and Missouri).
Pathophysiology : R. rickettsii is an obligate intracellular bacterium with tropism for vascular endothelial cells. Bacterial invasion causes widespread microvascular injury, vasculitis, microvascular thrombosis, increased vascular permeability, non-cardiogenic pulmonary edema, cerebral edema, and multi-organ ischemic necrosis.
Clinical Presentation :
Initial symptoms (days 1-3): Sudden onset of high fever (39.5-40.5°C), excruciating frontal headache, severe myalgias, photophobia, and nausea.
The Rash (days 2-4): Begins as small, blanching pink macules on the wrists, forearms, ankles, palms, and soles , spreading centripetally to the arms, legs, and trunk. Over subsequent days, it becomes petechial and purpuric, heralding extensive microvascular thrombosis.
Laboratory Hallmarks: Thrombocytopenia (<100,000/mcL), hyponatremia (<135 mEq/L), elevated transaminases, and elevated serum lactate.
Therapeutic Regimen : Doxycycline 100 mg PO or IV every 12 hours (pediatric dosing: 2.2 mg/kg/dose IV/PO every 12 hours , maximum 100 mg/dose) for 5 to 7 days, continuing until the patient has been afebrile for at least 72 hours.
Important
The Pediatric & Pregnancy Mandate for RMSF : Doxycycline is the first-line drug of choice for suspected RMSF across all age groups, including children under 8 years of age . Mortality in untreated RMSF exceeds 20-30%, and death occurs rapidly if treatment is delayed beyond the 5th day of symptoms. Multiple contemporary studies (endorsed by the CDC and the American Academy of Pediatrics) prove that short courses of doxycycline (up to 14 days) do not cause visible tooth staining or enamel hypoplasia in young children. In pregnant patients with suspected RMSF, doxycycline remains the drug of choice because maternal and fetal mortality from untreated RMSF vastly outweighs theoretical fetal risks. Never withhold or delay doxycycline while awaiting serologic antibody titers!
Lyme Disease ( Borrelia burgdorferi )
Transmission : Transmitted by Ixodes scapularis (blacklegged tick) in the Northeast and Upper Midwest. Tick attachment for at least 36 to 48 hours is required for transmission.
Stages & Manifestations :
Early Localized : Erythema migrans (EM) rash (expanding annular erythematous plaque ≥5 cm, classically with central clearing creating a bull's-eye appearance) appearing 7 to 14 days post-bite, accompanied by fatigue, headache, and arthralgias.
Early Disseminated : Multiple secondary EM lesions, cranial neuropathy (unilateral or bilateral Cranial Nerve VII / facial palsy), Lyme carditis (fluctuating high-grade AV block, PR interval >300 ms), and aseptic meningitis.
Late : Recurrent monoarticular or oligoarticular arthritis (typically involving the knee).
Pharmacotherapy :
Early Localized / Mild : Doxycycline 100 mg PO twice daily for 10 to 14 days. Alternatives in pregnancy or lactation: Amoxicillin 500 mg PO three times daily for 14 days or Cefuroxime axetil 500 mg PO twice daily for 14 days.
Lyme Carditis (Symptomatic, High-Degree AV Block, PR >300 ms) or CNS Disease (Meningitis) : Ceftriaxone 2 g IV once daily for 14 to 21 days until clinical stabilization, then step down to oral doxycycline.
Post-Exposure Prophylaxis (PEP) : Single dose Doxycycline 200 mg PO (pediatric: 4.4 mg/kg up to 200 mg) administered within 72 hours of tick removal, provided all criteria are met: tick is identified as an Ixodes species, attached for ≥36 hours, and local tick infection prevalence is ≥20%.